Drug Trial Radar · NCT00922714
Scandinavian Intensive Care Unit (ICU) Glutamine Study
Last checked: Nov 19, 2026Latest source record: Jun 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,000
Planned (sponsor's estimate)
Start
Oct 2003
Primary completion
May 2007
Study completion Aug 2009
Sponsor
- Lead sponsor
- Scandinavian Critical Care Trials GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective double-blinded placebo-controlled block randomized study in intensive care patients comparing intravenous glutamine supplementation to placebo. The hypothesis is an improvement of clinical outcome. The primary endpoint is a reduction in the Sequential Organ Failure Assessment (SOFA) score on day 7 of treatment.
Conditions
- ICU Patients
Interventions
GlutamineDrug
Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
saline (placebo)Drug
NaCl 0.9 g/L
Primary outcomes
What the sponsor says the trial is designed to measure.
- A reduction in SOFA-scoreTime frame: Day 7 of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Intensive Care Unit, Karolinska University Hospital Huddinge
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.